Source comparison
The Unfiltered Truth About CJC-1295 vs IGF-1 LR3
Here's the honest answer: most researchers combine CJC-1295 and IGF-1 LR3 without understanding receptor kinetics, and the result is wasted compound, unpredictable outcomes, and data that can't distinguish upstream effects from downstream effects. CJC-1295 wor
This comparison does not assign a generated winner or score.
- Here's the honest answer: most researchers combine CJC-1295 and IGF-1 LR3 without understanding receptor kinetics, and the result is wasted compound, unpredictable outcomes, and data that can't distinguish upstream effects from downstream effects. CJC-1295 works because it amplifies your endogenous GH machinery. But that machinery includes negative feedback loops. IGF-1 LR3 works because it bypasses those feedback loops entirely. But that means there's no physiological brake. Running both simultaneously at full dose doesn't double the anabolic signal; it saturates IGF-1 receptors, suppresses endogenous GH release through feedback inhibition, and creates a pharmacological environment that doesn't resemble either peptide's isolated mechanism. If your protocol genuinely requires both upstream amplification and downstream receptor activation, dose them sequentially. CJC-1295 weekly, IGF-1 LR3 daily starting 48 hours post-CJC dose. If your model has intact pituitary function and you want su
- The purity and consistency of the peptides matter more than the dosing schedule. CJC-1295 and IGF-1 LR3 are both hydrolytically unstable. Improper storage, contamination during reconstitution, or degraded peptide sequences produce inactive fragments that occupy receptors without triggering downstream signaling. Research-grade peptides from facilities like Real Peptides undergo amino-acid sequencing verification and purity assays (typically >98% by HPLC) to ensure the compound in the vial matches the structure required for receptor binding. Generic peptides without third-party verification frequently contain truncated sequences, oxidized methionine residues, or racemized amino acids. These variants bind to receptors but fail to activate them, creating false negatives in dose-response studies. If your CJC-1295 vs IGF-1 LR3 comparison shows no measurable difference between compounds, the first variable to check isn't the dose or timing. It's whether the peptides are pharmacologically acti